Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
about
Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresisL-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression.Current Experimental Studies of Gene Therapy in Parkinson's DiseaseEffects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathyDyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.Review: management of Parkinson's disease.Continuous drug delivery in Parkinson's disease.Dopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Impact of bilateral subthalamic stimulation on motor/cognitive functions in Parkinson's disease.Higher iron in the red nucleus marks Parkinson's dyskinesia.Drug Insight: new drugs in development for Parkinson's disease.Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson's disease and its evolution study.Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.Therapies for dopaminergic-induced dyskinesias in Parkinson disease.Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.The vesicular monoamine transporter 2: an underexplored pharmacological target.Drug safety evaluation of ropinirole prolonged release.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: a systematic review and meta-analysis.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.Cell transplantation and gene therapy in Parkinson's disease.Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.Treatment of advanced Parkinson's disease.Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
P2860
Q28833697-4103292E-74C1-4311-975D-9AEEB3BAD8D9Q33412141-F678DB4F-5C0D-4EA2-8CE4-C2D700C64C70Q33627771-6C0A4FAD-0485-4902-965D-B1C594DB0DC7Q33695388-7FE72922-A305-42A7-A260-07AA385EA052Q33834247-93C1BD45-CFAE-4508-BD68-4A9E8A454AF4Q34332812-67295A91-DAD0-4136-815F-CC9CA48743BEQ34390800-3E3EF928-2E6E-4788-93C0-0AB268AE5DF5Q34883582-5D8B09B4-F55A-4895-8402-124A8B579812Q35614156-977F253D-42C7-412C-9F0D-C8E3CA3B4CE4Q35943859-1F6D6564-8FA6-4CE4-909D-74066DD8E7D5Q36605028-B94DA35A-7FBF-44ED-8F75-B42978A66C5EQ36631654-919ABDCF-4E89-4C2A-A487-B8A34AAE8611Q36938097-65D532A0-2E6D-428A-95EB-4DB4BF8FCFE4Q36941752-0FEF6EF9-4ADE-43CF-A2C3-E2C04D24FED1Q37086136-1419DC69-1BC6-4356-AE8C-AD3A0C3CC100Q37090621-15A38AAE-2661-4A0E-BF64-77BB8B601001Q37507973-954F5E12-C2FD-46BF-A345-A9FED8EF5BF9Q37831397-4B75674E-5F19-4FD0-90C5-AC2D394583EDQ37855572-E294F0B7-8721-465B-B8F6-8EF259CCE0A7Q37890986-D3C374BA-288D-4F1F-B965-B882CAC4DE97Q37925513-AE6E1536-75F9-4EC3-821B-087F74C4DC06Q37973462-35714F90-646E-4311-8793-974C8C9449EFQ38176494-92ADA001-921C-488A-962F-4B79AD844328Q38184611-16C83DF5-5815-4943-9909-F9C5B0B7B526Q38215506-13F1A8A6-0E34-418D-A4D4-AE7D16EA1B42Q38239051-E85AD66F-0EC8-4F44-9F31-33CB8C2B3C93Q38262418-AF9E284A-FDDA-4298-AB45-594DD79E9C49Q38355582-956DA322-D06D-4FFD-9403-2F1024D36D1BQ38530328-3FC2F2FD-6442-4947-9425-18284782A715Q42011190-740C3D9B-1727-417A-AF55-11AB3185B794Q44297524-4DAB8283-2DC6-4619-8E08-E123C6C02ADAQ45951082-37CD1AAC-5AB5-4B3F-B7DB-7103DABF7A5EQ46119482-AE1E8596-0CB0-4506-ABDD-12B3E9978774Q54328579-D609A33D-8B0E-4A49-B743-1B3C90349C2FQ55645561-09C2D850-875F-4EDA-A4C7-ED7647646629Q57192035-015F4735-55AB-4B9B-AA39-29DF5BE833F1
P2860
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Drug insight: Continuous dopam ...... atment of Parkinson's disease.
@ast
Drug insight: Continuous dopam ...... atment of Parkinson's disease.
@en
type
label
Drug insight: Continuous dopam ...... atment of Parkinson's disease.
@ast
Drug insight: Continuous dopam ...... atment of Parkinson's disease.
@en
prefLabel
Drug insight: Continuous dopam ...... atment of Parkinson's disease.
@ast
Drug insight: Continuous dopam ...... atment of Parkinson's disease.
@en
P2860
P356
P1476
Drug insight: Continuous dopam ...... atment of Parkinson's disease.
@en
P2093
José A Obeso
P2860
P304
P356
10.1038/NCPNEURO0222
P577
2006-07-01T00:00:00Z